Fresh analysis reveals that people who discontinue new weight-loss injections like Wegovy and Mounjaro tend to recover shed pounds far faster than those who end conventional diet and exercise programs.
Published data in a prominent health publication demonstrates that while overweight individuals frequently drop substantial amounts of their body weight while on the medication, the mass returns at an estimated rate of 0.8 kg per month once they quit.
"Users purchasing these treatments must be informed of the potential of quick rebound weight gain when the medication is stopped," cautioned researcher Dr. Susan Jebb.
This pace of recovery suggests a return to original weight within about 18 months.
Analyzing Therapies
The analysis, which examined dozens of studies involving thousands of patients, compared the effects of GLP-1 agonists with other pills.
Scientists emphasize that individuals who lose weight through dieting typically experience a slower weight regain—approximately 0.1 kg a month—post-intervention.
The Reason for the Rapid Rebound
Nutrition scientists propose the mode of action of the injections is key to understanding the amplified regain.
These medications mimic a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of the hormone levels far above than normal may cause the body to produce less of its own natural hormone, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication means hunger is uncontrolled, making excessive eating far more likely."
A Lifelong Disease?
Health authorities recommend the injections for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals say that, considering the high risk of relapse, the therapy is often long-term.
This perspective is echoed by pharmaceutical companies, who say that the findings "emphasize the chronic nature of obesity," comparing it to managing diseases like hypertension.
User Testimonies
Users who have stopped the jabs explain a sudden resurgence of cravings.
"I experienced something flipping and you become extremely hungry," said an individual.
This difficulty is compounded if users have not developed lasting lifestyle or habit modifications during treatment.
Growing Use
Survey data show that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Adoption is higher among females compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than public health services.
Ultimately, experts caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone solution and long-term success likely depends on integrated behavioural support.
